RESUMEN
This is an analytical of changes that antibiotics cause on intestinal-microflora with special attention to the antibiotics used in the clinical practice of gastroenterology. We wish to special attention to antibiotics such as metronidazole, clarithromycin, fluoroquinolone, cephalosporin and imipenem. In each case changes produce by this drug and microbial resistance are analyzed. A prudential and justified use of this group of antibiotics is suggested.
Asunto(s)
Antibacterianos/farmacología , Intestinos/microbiología , Humanos , Intestinos/efectos de los fármacos , Gastropatías/tratamiento farmacológicoRESUMEN
This is an analytical of changes that antibiotics cause on intestinal-microflora with special attention to the antibiotics used in the clinical practice of gastroenterology. We wish to special attention to antibiotics such as metronidazole, clarithromycin, fluoroquinolone, cephalosporin and imipenem. In each case changes produce by this drug and microbial resistance are analyzed. A prudential and justified use of this group of antibiotics is suggested.
Asunto(s)
Humanos , Antibacterianos , Intestinos , GastropatíasRESUMEN
This is an analytical of changes that antibiotics cause on intestinal-microflora with special attention to the antibiotics used in the clinical practice of gastroenterology. We wish to special attention to antibiotics such as metronidazole, clarithromycin, fluoroquinolone, cephalosporin and imipenem. In each case changes produce by this drug and microbial resistance are analyzed. A prudential and justified use of this group of antibiotics is suggested.
RESUMEN
This is an analytical of changes that antibiotics cause on intestinal-microflora with special attention to the antibiotics used in the clinical practice of gastroenterology. We wish to special attention to antibiotics such as metronidazole, clarithromycin, fluoroquinolone, cephalosporin and imipenem. In each case changes produce by this drug and microbial resistance are analyzed. A prudential and justified use of this group of antibiotics is suggested. (AU)
Asunto(s)
Humanos , Antibacterianos/farmacología , Intestinos/microbiología , Gastropatías/tratamiento farmacológicoRESUMEN
BACKGROUND/AIMS: Oral quinolones have been suggested as treatment of cirrhotic patients with uncomplicated spontaneous bacterial peritonitis. To evaluate the efficacy of oral quinolones in all patients with this complication, oral ciprofloxacin after a short course of intravenous (i.v.) ciprofloxacin was compared to i.v. ciprofloxacin. METHODS: Eighty patients were allocated to receive ciprofloxacin i.v. 200 mg/12 h for 7 days (group A, n= 40) or i.v. 200 mg/12 h during 2 days followed by oral 500 mg/12 h for 5 days (group B, n=40). All patients with spontaneous bacterial peritonitis admitted to the hospital were included. Twenty-five variables obtained 48 h after treatment were introduced into univariate and multivariate analyses to identify predictors of survival and outcome. RESULTS: In the baseline condition, no differences were found between the two groups in clinical data, hepatic and renal function tests and Child Pugh score. The infection resolution rate was 76.3 % in group A and 78.4 % in group B, and hospital survival was 77.5% in both groups. In multivariate analysis serum creatinine and serum leukocytes 48 h after treatment were associated with prognosis. CONCLUSIONS: Oral ciprofloxacin after a short course of i.v. ciprofloxacin is effective in the treatment of spontaneous bacterial peritonitis. This regimen can be applied to all patients admitted to the hospital with this complication, and could be an alternative to treating these patients as outpatients.
Asunto(s)
Antiinfecciosos/uso terapéutico , Ciprofloxacina/uso terapéutico , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Peritonitis/tratamiento farmacológico , Administración Oral , Análisis de Varianza , Antiinfecciosos/administración & dosificación , Líquido Ascítico/microbiología , Ciprofloxacina/administración & dosificación , Creatinina/sangre , Femenino , Bacterias Gramnegativas/aislamiento & purificación , Infecciones por Bacterias Gramnegativas/sangre , Infecciones por Bacterias Gramnegativas/mortalidad , Bacterias Grampositivas/aislamiento & purificación , Infecciones por Bacterias Grampositivas/sangre , Infecciones por Bacterias Grampositivas/mortalidad , Humanos , Infusiones Intravenosas , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Peritonitis/sangre , Peritonitis/mortalidad , Tasa de SupervivenciaAsunto(s)
Seropositividad para VIH/complicaciones , Histoplasmosis/complicaciones , Enfermedades del Íleon/etiología , Adulto , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Constricción Patológica , Estudios de Seguimiento , Histoplasmosis/patología , Histoplasmosis/cirugía , Humanos , Enfermedades del Íleon/patología , Enfermedades del Íleon/cirugía , Íleon/patología , Itraconazol/administración & dosificación , Itraconazol/uso terapéutico , Masculino , Cuidados Posoperatorios , Factores de TiempoAsunto(s)
Humanos , Masculino , Femenino , Esófago de Barrett/epidemiología , Helicobacter pylori , Infecciones por Helicobacter/epidemiología , Adulto , Factores de Edad , Anciano , Argentina/epidemiología , Biopsia , Esófago de Barrett/microbiología , Esófago de Barrett/patología , Resumen en Inglés , Esófago/microbiología , Esófago/patología , Infecciones por Helicobacter/microbiología , Infecciones por Helicobacter/patología , Helicobacter pylori/aislamiento & purificación , Persona de Mediana EdadAsunto(s)
Humanos , Masculino , Femenino , Esófago de Barrett/epidemiología , Helicobacter pylori , Infecciones por Helicobacter/epidemiología , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Argentina/epidemiología , Esófago de Barrett/microbiología , Esófago de Barrett/patología , Biopsia , Resumen en Inglés , Esófago/microbiología , Esófago/patología , Helicobacter pylori/aislamiento & purificación , Infecciones por Helicobacter/microbiología , Infecciones por Helicobacter/patología , Persona de Mediana EdadRESUMEN
The authors evaluated the prevalence of colonize by Helicobacter Pylori in 21 adults patients with Barrett's esophagus; 12 males and 9 females; with ranges of age from 21 to 81 years and a medium of 56.4 years old. It was detected in 23.8% that Helicobacter Pylori was positive in Barrett's esophagus, being quite higher, 26.6% in patients over 50 years old. In the five cases with positive Helicobacter Pylori, the Barrett esophagus presented a fundic gastric mucosa and no one intestinal metaplasia. Helicobacter Pylori was not seen in esophageal biopsies from patients with reflux esophagitis without Barrett's esophagus. The clinical value of the Helicobacter Pylori finding in Barrett's esophagus and its importance of the following at long term must be explained and studied in the future, by the evaluation in numerous patients groups and prolonged follow-up.
Asunto(s)
Esófago de Barrett/epidemiología , Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Argentina/epidemiología , Esófago de Barrett/microbiología , Esófago de Barrett/patología , Biopsia , Esófago/microbiología , Esófago/patología , Femenino , Infecciones por Helicobacter/microbiología , Infecciones por Helicobacter/patología , Helicobacter pylori/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Factores SexualesRESUMEN
The authors evaluated the prevalence of colonize by Helicobacter Pylori in 21 adults patients with Barretts esophagus; 12 males and 9 females; with ranges of age from 21 to 81 years and a medium of 56.4 years old. It was detected in 23.8
that Helicobacter Pylori was positive in Barretts esophagus, being quite higher, 26.6
in patients over 50 years old. In the five cases with positive Helicobacter Pylori, the Barrett esophagus presented a fundic gastric mucosa and no one intestinal metaplasia. Helicobacter Pylori was not seen in esophageal biopsies from patients with reflux esophagitis without Barretts esophagus. The clinical value of the Helicobacter Pylori finding in Barretts esophagus and its importance of the following at long term must be explained and studied in the future, by the evaluation in numerous patients groups and prolonged follow-up.
RESUMEN
The authors evaluated the prevalence of colonize by Helicobacter Pylori in 21 adults patients with Barretts esophagus; 12 males and 9 females; with ranges of age from 21 to 81 years and a medium of 56.4 years old. It was detected in 23.8
that Helicobacter Pylori was positive in Barretts esophagus, being quite higher, 26.6
in patients over 50 years old. In the five cases with positive Helicobacter Pylori, the Barrett esophagus presented a fundic gastric mucosa and no one intestinal metaplasia. Helicobacter Pylori was not seen in esophageal biopsies from patients with reflux esophagitis without Barretts esophagus. The clinical value of the Helicobacter Pylori finding in Barretts esophagus and its importance of the following at long term must be explained and studied in the future, by the evaluation in numerous patients groups and prolonged follow-up.